A Phase 3 interventional study of Rosuvastatin and Atorvastatin in Hypercholesterolemia, sponsored by AstraZeneca. Completed at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-21.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 18th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2008, is one of 33 in phase 3, and was the 28th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 934 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 203 across the 57 interventional studies. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 59 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
60 studies in Hypercholesterolemia by AstraZeneca: 3 open now, 3 under way, 3 of them phase 3. Of 55 finished, 7 (13%) have results posted.
Among the 60 studies in Hypercholesterolemia by AstraZeneca, this one is the 16th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2008, is one of 25 in phase 3, and was the 33rd registered.
AstraZeneca’s Hypercholesterolemia studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 60 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
This trial is to compare the efficacy, safety and tolerability of Rosuvastatin with Atorvastatin by assessing the change of LDL-C in patients with hypercholesterolemia and history of coronary heart disease (CHD) or risk equivalent, or a 10 year CHD risk of no less than 10%, following 6-week treatment and a possible 6 week extension treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rosuvastatin 5mg qd
Drug: Rosuvastatin
Rosuvastatin 10mg qd
Drug: Rosuvastatin
Atorvastatin 10mg qd
Drug: Atorvastatin
Capsule/Tablet, oral, qd, 6 or 12 weeks
Also known as: Crestor
Capsule/Tablet, 10mg, oral, qd, 6 weeks
Also known as: Lipitor
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a two-sided significance level of 0.025 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.025 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 6
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in Total Cholesterol (TC ) at Week 6
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in Triglycerides (TG) at Week 6
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in Non High Density Lipoprotein-Cholesterol (nonHDL-C) at Week 6
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in Apolipoprotein B (ApoB) at Week 6
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 6
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (TC/HDL-C) at Week 6
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (LDL-C/HDL-C) at Week 6
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in Non High Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (nonHDL-C/HDL-C) at Week 6
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
Time frame: baseline, 6 weeks
Percentage Change From Baseline in Apolipoprotein B/Apolipoprotein A I (ApoB/ApoA-I) at Week 6
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
Time frame: baseline, 6 weeks
Percentage of Patients Achieved ATP III Guideline (2001) Low Density Lipoprotein Cholesterol (LDL-C) Goal at Week 6
The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL), non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL), non-HDL-C goal \< 3.36mmol/L (130mg/dL)
Time frame: week 6
6 weeksPercentage of Patients Achieved ATP III Guideline (2001) Non High Density Lipoprotein-Cholesterol (nonHDL-C) Goal at Week 6
The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL); non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL),non-HDL-C goal \< 3.36mmol/L (130mg/dL)
Time frame: week 6
Percentage of Patients Achieved National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Guideline (2001) Low Density Lipoprotein-Cholesterol (LDL-C) Goal After Titration
The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL), non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL), non-HDL-C goal \< 3.36mmol/L (130mg/dL)
Time frame: from week 6 to week 12
In total 934 patients were enrolled to the study, the study was conducted at 13 investigational sites in China. The first patient was enrolled on 27 May 2008, the last patient was completed on 16 Jul 2009.
| Milestone | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Started | 145 | 145 | 146 |
| Completed | 139 | 143 | 140 |
| Not completed | 6 | 2 | 6 |
| Withdrew: Withdrawal by subject | 4 | 1 | 2 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Adverse event | 2 | 0 | 2 |
| Withdrew: Reason not provided | 0 | 0 | 2 |
| Milestone | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Started | 36 | 23 | 0 |
| Completed | 33 | 23 | 0 |
| Not completed | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a two-sided significance level of 0.025 on ITT population.
| percent change | Rosuvastatin 5mg | Atorvastatin 10mg |
|---|---|---|
| Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg | -41.70 ± 2.62 | -38.67 ± 2.64 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.025 on ITT population.
| Percent change | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|
| Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg | -46.28 ± 2.62 | -38.67 ± 2.64 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
| percent change | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 6 | 5.63 ± 2.29 | 6.82 ± 2.29 | 3.64 ± 2.31 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
| percent change | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage Change From Baseline in Total Cholesterol (TC ) at Week 6 | -29.62 ± 1.92 | -33.14 ± 1.91 | -28.06 ± 1.93 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
| Percent change | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage Change From Baseline in Triglycerides (TG) at Week 6 | -20.09 ± 4.72 | -22.05 ± 4.69 | -20.67 ± 4.73 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
| percent change | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage Change From Baseline in Non High Density Lipoprotein-Cholesterol (nonHDL-C) at Week 6 | -38.60 ± 3.57 | -46.08 ± 3.57 | -38.50 ± 3.60 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
| percent change | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage Change From Baseline in Apolipoprotein B (ApoB) at Week 6 | -36.55 ± 2.40 | -41.21 ± 2.40 | -34.67 ± 2.41 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
| percent change | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 6 | 3.67 ± 1.99 | 4.25 ± 1.98 | 1.79 ± 2.00 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
| percent change | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (TC/HDL-C) at Week 6 | -32.95 ± 2.96 | -38.04 ± 2.96 | -31.92 ± 2.99 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
| percent change | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage Change From Baseline in Low Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (LDL-C/HDL-C) at Week 6 | -44.07 ± 3.17 | -50.27 ± 3.16 | -41.04 ± 3.19 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
| percent change | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage Change From Baseline in Non High Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (nonHDL-C/HDL-C) at Week 6 | -41.79 ± 11.54 | -56.63 ± 11.52 | -48.33 ± 11.64 |
Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.
| percent change | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage Change From Baseline in Apolipoprotein B/Apolipoprotein A I (ApoB/ApoA-I) at Week 6 | -37.62 ± 3.15 | -41.87 ± 3.14 | -35.15 ± 3.16 |
The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL), non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL), non-HDL-C goal \< 3.36mmol/L (130mg/dL)
| percentage of patients | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage of Patients Achieved ATP III Guideline (2001) Low Density Lipoprotein Cholesterol (LDL-C) Goal at Week 6 | 61.0 | 79.1 | 58.3 |
The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL); non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL),non-HDL-C goal \< 3.36mmol/L (130mg/dL)
| percentage of patients | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| 6 weeksPercentage of Patients Achieved ATP III Guideline (2001) Non High Density Lipoprotein-Cholesterol (nonHDL-C) Goal at Week 6 | 66.9 | 78.4 | 60.4 |
The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL), non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL), non-HDL-C goal \< 3.36mmol/L (130mg/dL)
| percentage of patients | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Percentage of Patients Achieved National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Guideline (2001) Low Density Lipoprotein-Cholesterol (LDL-C) Goal After Titration | 41.2 | 47.6 | — |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin 5mg | — | 1/145 (0.7%) | 5/145 (3.4%) |
| Rosuvastatin 10mg | — | 0/145 (0%) | 3/145 (2.1%) |
| Atorvastatin 10mg | — | 1/146 (0.7%) | 0/146 (0%) |
| Event | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Foot FractureInjury, poisoning and procedural complications | 1/145 | 0/145 | 0/146 |
| Humerus FractureInjury, poisoning and procedural complications | 0/145 | 0/145 | 1/146 |
| Event | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg |
|---|---|---|---|
| Blood Creatine Phosphokinase IncreasedInvestigations | 2/145 | 3/145 | 0/146 |
| Alanine AminotransferaseInvestigations | 2/145 | 0/145 | 0/146 |
| MyalgiaRenal and urinary disorders | 1/145 | 0/145 | 0/146 |
| Age Continuous(Years) | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg | Total |
|---|---|---|---|---|
| Mean | 60.4 ± 8.51 | 59.7 ± 10.57 | 58.4 ± 9.29 | 59.5 ± 9.51 |
| Sex: Female, Male(Participants) | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg | Total |
|---|---|---|---|---|
| Female | 84 | 85 | 77 | 246 |
| Male | 52 | 54 | 62 | 168 |
| Race/Ethnicity, Customized(Participants) | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 136 | 139 | 139 | 414 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Nativ Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 |
| Low density lipoprotein cholesterol (LDL-C level)(mmol/L) | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg | Total |
|---|---|---|---|---|
| Mean | 4.242 ± 0.6769 | 4.131 ± 0.6818 | 4.213 ± 0.6617 | 4.186 ± 0.6717 |
| triglyceride (TG) level(mmol/L) | Rosuvastatin 5mg | Rosuvastatin 10mg | Atorvastatin 10mg | Total |
|---|---|---|---|---|
| Mean | 1.921 ± 0.7825 | 2.042 ± 0.9164 | 2.061 ± 0.8971 | 1.991 ± 0.8494 |
The record gives a start of May 2008, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin